News and breakthroughs in tissue analysis, biomarkers, and pathology technology.
January 26, 2018 – Flagship is proud to partner with Summit Therapeutics in its efforts to advance therapies for patients with Duchenne Muscular Dystrophy (DMD).
Comprehensive catalog of assays advance biomarker programs Westminster, CO, January 16, 2018 – Flagship Biosciences has introduced a new menu of services to help drug
Flagship Biosciences Presents PD-L1 Scoring Method at SITC 2017 that could Eliminate Reliance on Complex Multiplex IHC Assays
Novel cTA™-based morphometric biomarker interpretation approach quantifies immune cells in tumor tissues and has potential to revolutionize PD-L1 diagnostics landscape National Harbor, MD – November
Flagship Biosciences, Inc. Receives Prestigious Best Research Award for Poster on PD-L1 Harmonization at Pathology Visions 2017 Conference
Westminster, CO, Oct. 4, 2017 – Flagship Biosciences was honored to receive the award for Best Poster in the Research Category at the Pathology Visions
Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summit’s PhaseOut DMD Clinical Trial
CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society St. Malo, France,
Get the Whole Picture with both Content and Context August 9, 2017 – Westminster, CO – Flagship Biosciences, the leading partner for drug developers investigating